ReviewCancer medicine2022

Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine-refractory differentiated thyroid cancer.

Miguel-Ángel Berciano-GuerreroPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.